Antihypertensive drug therapy and coronary heart disease risk

Coronary heart disease (CHD) is the major cause of death in the United States. Major modifiable risk factors for CHD are hypertension, hypercholesterolemia, and cigarette smoking, with concomitant risk factors, especially left ventricular hypertrophy, that act synergistically to significantly increase overall risk. Antihypertensive therapy, while reducing the incidence of stroke, has not consistently reduced the incidence of CHD. This may be a result, in part, of adverse effects on the metabolic profile, especially on blood lipids, which are induced by diuretics and certain [beta]-blockers. Other antihypertensive agents appear to be either lipid neutral such as calcium channel blockers and angiotensin-converting enzyme inhibitors, or lipid positive, such as selective [alpha.sub.1]-blockers. The choice of initial antihypertensive therapy should be made with all of a patient's risk factors in mind. In addition to the drugs recommended in the 1988 Guidelines of the Joint National Committee an Detection, Evaluation and Treatment of High Blood Pressure, selective [alpha.sub.1]-blockers should also be considered since they improve the lipid profile as well as reduce blood pressure.
Despite a decline in its incidence in recent years, coronary heart disease (CHD) is still the major cause of death in the United States. Recent estimates show that 5.4 million [...]